|Systematic (IUPAC) name|
|2,2-dichlor-N- [(aR,bR)-b-hydroxy-a-hydroxymethyl- 4-nitrophenethyl] acetamide|
|ATC code||D06 D10AF03 G01AA05 J01BA01 S01AA01 S02AA01 S03AA08|
|Mol. mass||323.132 g/mol|
|Half life||1.5–4.0 hours|
C (A topical)
ocular P, else POM (UK)
|Routes||Topical (ocular), oral, IV, IM|
It was the first antibiotic to be manufactured synthetically on a large scale. Chloramphenicol is effective against a wide variety of microorganisms; it is still very widely used in low income countries because it is exceedingly cheap, but has fallen out of favour in the West due to a very rare but very serious side effect: aplastic anemia.
The usual dose is 50 mg/kg/day in four divided doses: the usual dose in an adult male is therefore around 750 mg four times daily; this dose is doubled in severe illness. Half the dose is used in premature babies or neonates, because they do not metabolise the drug as effectively.
Chloramphenicol is available as 250 mg capsules or as a liquid (125 mg/5 ml). In some countries, chloramphenicol is sold as chloramphenicol palmitate ester. Chloramphenicol palmitate ester is inactive, and is hydrolysed to active chloramphenicol in the small intestine. There is no difference in bioavailability between chloramphenicol and chloramphenicol palmitate.
The intravenous (IV) preparation of chloramphenicol is the succinate ester, because pure chloramphenicol does not dissolve in water. This creates a problem: chloramphenicol succinate ester is an inactive prodrug and must first be hydrolysed to chloramphenicol; the hydrolysis process is incomplete and 30% of the dose is lost unchanged in the urine, therefore serum concentrations of chloramphenicol are only 70% of those achieved when chloramphenicol is given orally. For this reason, the chloramphenicol dose needs to be increased to 75 mg/kg/day when administered IV in order to achieve levels equivalent to the oral dose. The oral route is therefore preferred to the intravenous route.
Manufacture of oral chloramphenicol in the U.S. stopped in 1991, because the vast majority of chloramphenicol-associated cases of aplastic anaemia are associated with the oral preparation. There is now no oral formulation of chloramphenicol available in the U.S., although there is no theoretical reason why the intravenous preparation should not be equally effective (or perhaps even more effective) when taken by mouth.
Plasma levels of chloramphenicol must be monitored in neonates and in patients with abnormal liver function. It is recommended that plasma levels be monitored in all children under the age of 4, the elderly and patients with renal failure. Peak levels (1 hour after the dose is given) should be 15–25 mg/l; trough levels (taken immediately before a dose) should be less than 15 mg/l.
Chloramphenicol and the liver
Chloramphenicol is metabolised by the liver to chloramphenicol glucuronate (which is inactive). In liver impairment, the dose of chloramphenicol must therefore be reduced. There is no standard dose reduction for chloramphenicol in liver impairment, and the dose should be adjusted according to measured plasma concentrations.
Chloramphenicol and the kidneys
The majority of the chloramphenicol dose is excreted by the kidneys as the inactive metabolite, chloramphenicol glucuronate. Only a tiny fraction of the chloramphenicol is excreted by the kidneys unchanged. It is suggested that plasma levels be monitored in patients with renal impairment, but this is not mandatory. Chloramphenicol succinate ester (the inactive intravenous form of the drug) is readily excreted unchanged by the kidneys, more so than chloramphenicol base, and this is the major reason why levels of chloramphenicol in the blood are much lower when given intravenously than orally.
Oily chloramphenicol (or chloramphenicol oil suspension) is a long-acting preparation of chloramphenicol first introduced by Roussel in 1954; marketed as Tifomycine®, it was originally used as a treatment for typhoid. Roussel stopped production of oily chloramphenicol in 1995; the International Dispensary Association has manufactured it since 1998, first in Malta and then in India from December 2004.
Oily chloramphenicol is recommended by the World Health Organization (WHO) as the first line treatment of meningitis in low-income countries and appears on the essential drugs list. It was first used to treat meningitis in 1975 and there have been numerous studies since demonstrating its efficacy. It is the cheapest treatment available for meningitis (US$5 per treatment course, compared to US$30 for ampicillin and US$15 for five days of ceftriaxone). It has the great advantage of requiring only a single injection, whereas ceftriaxone is traditionally given daily for five days. This recommendation may yet change now that a single dose of ceftriaxone (cost US$3) has been shown to be equivalent to one dose of oily chloramphenicol.
Oily chloramphenicol is not currently available in the U.S. or Europe.
Chloramphenicol eye drops
In the West, chloramphenicol is still widely used in topical preparations (ointments and eye drops) for the treatment of bacterial conjunctivitis. Isolated cases report of aplastic anaemia following chloramphenicol eyedrops exist, but the risk is estimated to be less than 1 in 224,716 prescriptions.
Chloramphenicol is extremely lipid soluble, it remains relatively unbound to protein and is a small molecule: it has a large apparent volume of distribution of 100 litres and penetrates effectively into all tissues of the body, including the brain. The concentration achieved in brain and cerebrospinal fluid (CSF) is around 30 to 50% even when the meninges are not inflamed; this increases to as high as 89% when the meninges are inflamed.
Because it functions by inhibiting bacterial protein synthesis, chloramphenicol has a very broad spectrum of activity: it is active against Gram-positive bacteria (including most strains of MRSA), Gram-negative bacteria and anaerobes. It is not active against Pseudomonas aeruginosa or Enterobacter species. It has some activity against Burkholderia pseudomallei, but is no longer routinely used to treat infections caused by this organism (it has been superseded by ceftazidime and meropenem). In the West, chloramphenicol is mostly restricted to topical uses because of the worries about the risk of aplastic anaemia.
The original indication of chloramphenicol was in the treatment of typhoid, but the now almost universal presence of multi-drug resistant Salmonella typhi has meant that it is seldom used for this indication except when the organism is known to be sensitive. Chloramphenicol may be used as a second-line agent in the treatment of tetracycline-resistant cholera.
Because of its excellent CSF penetration (far superior to any of the cephalosporins), chloramphenicol remains the first choice treatment for staphylococcal brain abscesses. It is also useful in the treatment of brain abscesses due to mixed organisms or when the causative organism is not known.
Chloramphenicol is active against the three main bacterial causes of meningitis: Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae. In the West, chloramphenicol remains the drug of choice in the treatment of meningitis in patients with severe penicillin or cephalosporin allergy and GPs are recommended to carry intravenous chloramphenicol in their bag. In low income countries, the WHO recommend that oily chloramphenicol be used first-line to treat meningitis.
Chloramphenicol has been used in the U.S. in the initial empirical treatment of children with fever and a petechial rash, when the differential diagnosis includes both Neisseria meningitidis septicaemia as well as Rocky Mountain spotted fever, pending the results of diagnostic investigations.
The most serious side effect of chloramphenicol treatment is aplastic anaemia. This effect is rare and is generally fatal: there is no treatment and there is no way of predicting who may or may not get this side effect. The effect usually occurs weeks or months after chloramphenicol treatment has been stopped and there may be a genetic predisposition. It is not known whether monitoring the blood counts of patients can prevent the development of aplastic anaemia, but it is recommended that patients have a blood count checked twice weekly while on treatment. The highest risk is with oral chloramphenicol (affecting 1 in 24,000–40,000) and the lowest risk occurs with eye drops (affecting less than 1 in 224,716 prescriptions).
Thiamphenicol is a related compound with a similar spectrum of activity that is available in Italy and China for human use, and has never been associated with aplastic anaemia. Thiamphenicol is available in the U.S. and Europe as a veterinary antibiotic, and is not approved for use in humans.
Bone marrow suppression
It is common for chloramphenicol to cause bone marrow suppression during treatment: this is a direct toxic effect of the drug on human mitochondria. This effect manifests first as a fall in haemoglobin levels and occurs quite predictably once a cumulative dose of 20 g has been given. This effect is fully reversible once the drug is stopped and does not predict future development of aplastic anaemia.
Gray baby syndrome
Intravenous chloramphenicol use has been associated with the so called gray baby syndrome. This phenomenon occurs in newborn infants because they do not yet have fully functional liver enzymes, and so chloramphenicol remains unmetabolized in the body. This causes several adverse effects, including hypotension and cyanosis. The condition can be prevented by using chloramphenicol at the recommended doses and monitoring blood levels.
Mechanism and resistance
Chloramphenicol is bacteriostatic (that is, it stops bacterial growth). It functions by inhibiting peptidyl transferase, preventing peptide bond formation. While chloramphenicol and the macrolide class of antibiotics both interact with the 50S ribosomal subunit, chloramphenicol is not a macrolide. Furthermore, their mechanisms are slightly different. While chloramphenicol directly interferes with substrate binding, macrolides sterically block the progression of the growing peptide.
There are three mechanisms of resistance to chloramphenicol: reduced membrane permeability, mutation of the 50S ribosomal subunit and elaboration of chloramphenicol acetyltransferase. It is easy to select for reduced membrane permability to chloramphenicol in vitro by serial passage of bacteria, and this is the most common mechanism of low-level chloramphenicol resistance. High level resistance is conferred by the cat-gene; this gene codes for an enzyme called chloramphenicol acetyltransferase which inactivates chloramphenicol by covalently linking one or two acetyl groups, derived from acetyl-S-coenzyme A, to the hydroxyl groups on the chloramphenicol molecule. The acetylation prevents chloramphenicol from binding to the ribosome. Resistance-conferring mutations of the 50S ribosomal subunit are rare.
Chloramphenicol resistance may be carried on a plasmid that also codes for resistance to other drugs. One example is the ACCoT plasmid (A=ampicillin, C=chloramphenicol, Co=co-trimoxazole, T=tetracycline) which mediates multi-drug resistance in typhoid (also called R factors).
Chloramphenicol has a long history and therefore a multitude of alternative names in many different countries:
- Chloromycetin (U.S., intravenous preparation)
- Chlorsig (U.S., Australia, eye drops)
- Kemicetine (UK, intravenous preparation)
- Optrex Infected Eyes (UK, eye drops)
- Silmycetin (Thailand, eye drops)
- Synthomycine (Israel, eye ointment)
- Tifomycine (France, oily chloramphenicol)
- 13-153f. at Merck Manual of Diagnosis and Therapy Professional Edition
- MedlinePlus DrugInfo uspdi-202125
- University of Pennsylvania
Antibiotics and chemotherapeutics for dermatological use (D06)
|Antibiotics: tetracycline and derivatives||Demeclocycline - Chlortetracycline - Oxytetracycline - Tetracycline|
|Antibiotics: other||Fusidic acid - Chloramphenicol - Neomycin - Bacitracin - Gentamicin - Tyrothricin - Mupirocin - Nadifloxacin - Virginiamycin - Rifaximin - Amikacin|
|Chemotherapeutics: sulfonamides||Silver sulfadiazine - Sulfathiazole - Mafenide - Sulfamethizole - Sulfanilamide - Sulfamerazine|
|Chemotherapeutics: antivirals||Idoxuridine - Tromantadine - Aciclovir - Podophyllotoxin - Inosine - Penciclovir - Lysozyme - Ibacitabine - Edoxudine - Imiquimod - Docosanol|
Gynecological anti-infectives and antiseptics (G01)
|Antibiotics||polyene antimycotic (Nystatin, Natamycin, Amphotericin B) - Candicidin - Chloramphenicol - Hachimycin - Oxytetracycline - Carfecillin - Mepartricin - Clindamycin - Pentamycin|
|Quinoline derivatives||Diiodohydroxyquinoline - Clioquinol - Chlorquinaldol - Dequalinium - Broxyquinoline - Oxyquinoline|
|Organic acids||Lactic acid - Acetic acid - Ascorbic acid|
|Imidazole derivatives||Metronidazole - Clotrimazole - Miconazole - Econazole - Ornidazole - Isoconazole - Tioconazole - Ketoconazole - Fenticonazole - Azanidazole - Propenidazole - Butoconazole - Omoconazole - Oxiconazole - Flutrimazole|
|Other||Clodantoin - Inosine - Policresulen - Nifuratel - Furazolidone - Methylrosaniline - Povidone-iodine - Ciclopirox - Protiofate - Lactobacillus fermentum - Copper usnate|
Antibacterials for systemic use: amphenicols (J01B)
|Chloramphenicol - Thiamphenicol - Florfenicol|
|Anti-infectives||Chloramphenicol - Nitrofural - Boric acid - Aluminium acetotartrate - Clioquinol - Hydrogen peroxide - Neomycin - Tetracycline - Chlorhexidine - Acetic acid - Polymyxin B - Rifamycin - Miconazole - Gentamicin|
|Corticosteroids||Hydrocortisone - Prednisolone - Dexamethasone - Betamethasone|
|Other otologicals||Lidocaine - Cocaine|
- ↑ Glazko AJ, Dill WA, Kinkel AW, et al. (1977). "Absorption and excretion of parenteral doses of chloramphenicol sodium succinate in comparison with per oral doses of chloramphenicol (abstract)". Clin Pharmacol Ther 21: 104.
- ↑ Bhutta Z, Niazi S, Suria A (Mar-Apr 1992). "Chloramphenicol clearance in typhoid fever: implications for therapy.". Indian J Pediatr 59 (2): 213-9. PMID 1398851.
- ↑ Rey M, Ouedraogo L, Saliou P, Perino L (1976). "Traitement minute de la méningite cérébrospinale épidémique par injection intramusculaire unique de chloramphénicol (suspension huileuse)". Médecine et Maladies Infectieuses 6: 120–24.
- ↑ Wali S, Macfarlane J, Weir W, Cleland P, Ball P, Hassan-King M, Whittle H, Greenwood B (1979). "Single injection treatment of meningococcal meningitis. 2. Long-acting chloramphenicol.". Trans R Soc Trop Med Hyg 73 (6): 698-702. PMID 538813.
- ↑ Puddicombe J, Wali S, Greenwood B (1984). "A field trial of a single intramuscular injection of long-acting chloramphenicol in the treatment of meningococcal meningitis.". Trans R Soc Trop Med Hyg 78 (3): 399-403. PMID 6464136.
- ↑ Pécoul B, Varaine F, Keita M, Soga G, Djibo A, Soula G, Abdou A, Etienne J, Rey M (Oct 5 1991). "Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis.". Lancet 338 (8771): 862-6. PMID 1681224.
- ↑ Nathan N, Borel T, Djibo A, et al. (2005). "Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study". Lancet 366 (9482): 308–13. PMID 16039333.
- ↑ 8.0 8.1 Lancaster T, Stewart AM, Jick H (1998). "Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database". Brit Med J 316: 667. PMID 9522792.
- ↑ "Iron Supplements". Pill Book, The (12th revised ed.). (2006). Ed. Harold M. Silverman, Pharm.D. (editor-in-chief). New York: Bantam Dell. pp. 593–596. ISBN 978-0-553-58892-7.
- ↑ Neu HC, Gootz TD (1996). Antimicrobial Chemotherapy:Antimicrobial Inhibitors of Ribosome Function.. In: Baron's Medical Microbiology (Baron S et al, eds.), 4th ed., Univ of Texas Medical Branch. (via NCBI Bookshelf) ISBN 0-9631172-1-1.
- ↑ Rich M, Ritterhoff R, Hoffmann R (Dec 1950). "A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy.". Ann Intern Med 33 (6): 1459-67. PMID 14790529.
- ↑ Nagao T, Mauer A (1969). "Concordance for drug-induced aplastic anemia in identical twins.". N Engl J Med 281 (1): 7-11. PMID 5785754.
- ↑ Holt R (1967). "The bacterial degradation of chloramphenicol". Lancet i: 1259.
- ↑ Wallerstein R, Condit P, Kasper C, Brown J, Morrison F (Jun 16 1969). "Statewide study of chloramphenicol therapy and fatal aplastic anemia.". JAMA 208 (11): 2045-50. PMID 5818983.
- ↑ Shu X, Gao Y, Linet M, Brinton L, Gao R, Jin F, Fraumeni J (Oct 24 1987). "Chloramphenicol use and childhood leukaemia in Shanghai.". Lancet 2 (8565): 934-7. PMID 2889862.
- ↑ McIntyre J, Choonara I (2004). "Drug toxicity in the neonate.". Biol Neonate 86 (4): 218-21. PMID 15249753.
- ↑ Piñeiro-Carrero V, Piñeiro E (2004). "Liver.". Pediatrics 113 (4 Suppl): 1097-106. PMID 15060205.
- ↑ Feder H (1986). "Chloramphenicol: what we have learned in the last decade.". South Med J 79 (9): 1129-34. PMID 3529436.
- ↑ Mulhall A, de Louvois J, Hurley R (1983). "Chloramphenicol toxicity in neonates: its incidence and prevention." (Scanned copy & PDF). Br Med J (Clin Res Ed) 287 (6403): 1424-7. PMID 6416440.
- ↑ Forster J, Hufschmidt C, Niederhoff H, Künzer W (1985). "[Need for the determination of chloramphenicol levels in the treatment of bacterial-purulent meningitis with chloramphenicol succinate in infants and small children]". Monatsschr Kinderheilkd 133 (4): 209-13. PMID 4000136.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies